Expert Highlights Tolerability and Safety of Ziftomenib in Phase 1 Trial

News
Video

An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.

During a conversation with CancerNetwork® regarding the phase 1/2 KOMET-001 trial (NCT04067336), Harry Erba, MD, indicated that 4 of 20 patients with NPM1-mutated relapsed/refractory acute myeloid leukemia developed differentiation syndrome following treatment with 600 mg of ziftomenib.


In the NPM1 group, all but 1 event was grade 1/2. Notably, hydroxyurea and dexamethasone were used to manage events of differentiation syndrome at a dose of 10 mg twice a day.

However, Erba, a hematologic oncologist at Duke Health, also indicated that patients with KMT2A-rearranged disease experienced an increase in differentiation syndrome. This was particularly noted in patients associated with low response to treatment, which could be due to treatment withdrawal.

Transcript:

At the 600 mg dose, in the NPM1-mutated patient population, we did not see any significant safety considerations. In fact, among patients with an NMP1 mutation treated with ziftomenib at 600 mg daily, we saw 4 patients with differentiation syndrome, all of [whom] were easily managed with appropriate dosing of hydroxyurea and dexamethasone when necessary at 10 mg twice daily.

We did not see any significant GI [gastrointestinal] toxicity, [nor] did we see Qt prolongation. There was no obvious signal for an interaction with SYP-3a/4 inhibitors.

On the other hand, in patients with the KMT2A-rearranged disease, we did see a significant safety concern for differentiation syndrome in those patients associated with a low response, likely due to early withdrawal of the drug because of the concern of a rapid proliferation of the blasts and these extramedullary sites of disease.

Reference

Erba HP, Fathi AT, Issa GC, et al. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022; 140(suppl 1):153-156. doi:10.1182/blood-2022-167412

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.